KBC Group NV - NEKTAR THERAPEUTICS ownership

NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 237 filers reported holding NEKTAR THERAPEUTICS in Q1 2021. The put-call ratio across all filers is 0.96 and the average weighting 0.1%.

Quarter-by-quarter ownership
KBC Group NV ownership history of NEKTAR THERAPEUTICS
ValueSharesWeighting
Q1 2023$11
-78.8%
16,2330.0%0.00%
Q4 2022$52
-99.9%
16,2330.0%0.00%
Q3 2022$52,000
-16.1%
16,2330.0%0.00%
Q2 2022$62,000
+24.0%
16,233
+75.4%
0.00%
Q1 2022$50,000
-56.9%
9,254
+8.0%
0.00%
Q4 2021$116,000
-11.5%
8,572
+17.3%
0.00%
Q3 2021$131,000
-47.6%
7,308
-50.0%
0.00%
Q2 2021$250,000
-14.4%
14,6160.0%0.00%
-100.0%
Q1 2021$292,000
-78.6%
14,6160.0%0.00%0.0%
Q4 2020$1,366,000
+642.4%
14,616
+31.6%
0.00%0.0%
Q3 2020$184,000
-94.8%
11,110
-92.8%
0.00%
-91.7%
Q2 2020$3,558,000
-44.4%
153,612
-57.2%
0.01%
-77.8%
Q1 2020$6,400,000
-36.2%
358,535
-22.8%
0.05%
-14.3%
Q4 2019$10,028,000
+1268.1%
464,605
+1054.0%
0.06%
+1160.0%
Q3 2019$733,000
+38.3%
40,260
+170.2%
0.01%
+25.0%
Q2 2019$530,000
+6.0%
14,8980.0%0.00%0.0%
Q1 2019$500,000
+27.6%
14,898
+24.9%
0.00%0.0%
Q4 2018$392,000
-44.8%
11,925
+2.4%
0.00%
-20.0%
Q3 2018$710,000
+24.8%
11,6450.0%0.01%0.0%
Q2 2018$569,000
-61.4%
11,645
-52.9%
0.01%
-61.5%
Q4 2017$1,476,000
+81.1%
24,716
-47.9%
0.01%
+30.0%
Q3 2016$815,000
+161.2%
47,413
+116.3%
0.01%
+150.0%
Q2 2016$312,00021,9170.00%
Other shareholders
NEKTAR THERAPEUTICS shareholders Q1 2021
NameSharesValueWeighting ↓
Cormorant Asset Management, LP 1,828,400$89,281,0006.61%
Cormorant Asset Management, LP 1,500,000$73,245,0005.42%
Camber Capital Management LP 2,000,000$97,660,0003.76%
Rhenman & Partners Asset Management AB 617,652$30,160,0003.09%
BRIDGER MANAGEMENT, LLC 1,134,414$55,393,0003.00%
First Light Asset Management, LLC 374,251$18,275,0002.84%
Gs Investments, Inc. 54,000$2,636,820,0001.97%
SABBY MANAGEMENT, LLC 241,922$11,813,0001.82%
QUANTRES ASSET MANAGEMENT Ltd 50,000$2,441,0001.41%
Tibra Equities Europe Ltd 173,183$8,457,0001.27%
View complete list of NEKTAR THERAPEUTICS shareholders